2 terminated, 1 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Roberto Pili: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Entinostat, Nivolumab, Ipilimumab - Renal Cell Carcinoma | Phase 2 | Terminated | Roberto Pili | 12 | 2018-07-31 | 2024-09-03 |
| High Dose IL 2 and Entinostat in RCC Entinostat, Interleukin-2 - Renal Cell Carcinoma | Phase 2 | Active not recruiting | Roberto Pili | 46 | 2018-05-24 | 2023-09-01 |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Atezolizumab, Bevacizumab, Entinostat - Metastatic Cancer, Renal Cancer | Phase 1 / Phase 2 | Terminated | Roberto Pili | 31 | 2017-06-29 | 2025-03-20 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (1) · Neoplasm Metastasis (1)
entinostat (3) · Bevacizumab (1) · Interleukin-2 (1) · Ipilimumab (1) · Nivolumab (1) · aldesleukin (1) · atezolizumab (1)
United States (3)
Nabil Adra, MD (1)